FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213010911> ?p ?o ?g. }

• W3213010911 endingPage "1744" @default.
• W3213010911 startingPage "1744" @default.
• W3213010911 abstract "Abstract Background Axi-cel is approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma since 2017 and has demonstrated efficacy and durability but with significant side effects, namely cytokine release syndrome (CRS) and neurotoxicity (ICANS). In patients receiving axi-cel for aggressive lymphomas, any grade ICANS occurs at a rate of 50% and grade 3/4 occurs about 35% of the time. The mechanism underlying ICANS remains unclear. The current working hypothesis is that endothelial injury caused by the disease and lymphodepleting chemotherapy leads to breakdown of the blood-brain-barrier. Following activation of axi-cel, cytokines are trafficked into the central nervous system leading to local production of cytokines and the clinical syndrome observed. ICANS is treated with systemic steroids with good CNS penetration. Statins have been shown to stabilize the endothelium and have anti-inflammatory effects. We are currently evaluating the safety and feasibility of administering simvastatin to stabilize the endothelium in addition to dexamethasone delivered intrathecally to prevent the occurrence and decrease the severity of neurotoxicity. Methods: This is a feasibility study combining simvastatin 40 mg orally, daily, starting at least 5 days prior to apheresis in addition to dexamethasone delivered intrathecally on days -1, +6, +13 in relation to axi-cel. A schema of the trial is presented in figure 1. This is registered on Clinicaltrials.gov number (NCT04514029). Results: We have accrued 6/20 planned patients with r/r DLBCL who received axi-cel per institutional guidelines. One passed away prior to apheresis due to disease progression and was non-evaluable. Table 1 shows the patient characteristics. With a median follow up of 123 days (50-245), all patients achieved a complete response and remained alive. Table 2 summarizes the feasibility, safety, and dose-density received out of prescribed. None of the 5 patients had grade 3 or 4 ICANS and only 1 patient had grade 1 neurotoxicity (Table 3). A cytokine analysis and markers of endothelial and neuronal activation is underway. Discussion: In a preliminary analysis, simvastatin and intrathecal dexamethasone appears to be feasible to administer, safe and efficacious in a population of patients receiving axi-cel for relapsed and refractory DLBCL. There appears to be a signal in abrogating neurotoxicity without any effect on the efficacy of axi-cel. This will allow for a safer delivery of axi-cel and improve access to this treatment. This study is ongoing. Figure 1 Figure 1. Disclosures Bachanova: FATE: Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Research Funding; KaryoPharma: Membership on an entity's Board of Directors or advisory committees; Gamida Cell: Membership on an entity's Board of Directors or advisory committees, Research Funding. Weisdorf: Fate Therapeutics: Research Funding; Incyte: Research Funding. Miller: Wugen: Membership on an entity's Board of Directors or advisory committees; GT Biopharma: Consultancy, Patents & Royalties, Research Funding; Vycellix: Consultancy; ONK Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Magenta: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; Fate Therapeutics, Inc: Consultancy, Patents & Royalties, Research Funding. Janakiram: FATE, Nektar Therapeutics: Research Funding; Bristol Meyer Squibb, Kyowa Kirin, ADCT Therapeutics: Honoraria. OffLabel Disclosure: Simvastatin is an HMG-CoA reductase inhibitor approved for hyperlipidemia and cardiovascular health." @default.
• W3213010911 created "2021-11-22" @default.
• W3213010911 creator A5002205597 @default.
• W3213010911 creator A5026490608 @default.
• W3213010911 creator A5027151969 @default.
• W3213010911 creator A5048939308 @default.
• W3213010911 creator A5066966509 @default.
• W3213010911 creator A5067489954 @default.
• W3213010911 creator A5070132319 @default.
• W3213010911 creator A5080104357 @default.
• W3213010911 creator A5087749554 @default.
• W3213010911 creator A5087850908 @default.
• W3213010911 date "2021-11-05" @default.
• W3213010911 modified "2023-09-28" @default.
• W3213010911 title "Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi-Cel) Treatment" @default.
• W3213010911 doi "https://doi.org/10.1182/blood-2021-149607" @default.
• W3213010911 hasPublicationYear "2021" @default.
• W3213010911 type Work @default.
• W3213010911 sameAs 3213010911 @default.
• W3213010911 citedByCount "0" @default.
• W3213010911 crossrefType "journal-article" @default.
• W3213010911 hasAuthorship W3213010911A5002205597 @default.
• W3213010911 hasAuthorship W3213010911A5026490608 @default.
• W3213010911 hasAuthorship W3213010911A5027151969 @default.
• W3213010911 hasAuthorship W3213010911A5048939308 @default.
• W3213010911 hasAuthorship W3213010911A5066966509 @default.
• W3213010911 hasAuthorship W3213010911A5067489954 @default.
• W3213010911 hasAuthorship W3213010911A5070132319 @default.
• W3213010911 hasAuthorship W3213010911A5080104357 @default.
• W3213010911 hasAuthorship W3213010911A5087749554 @default.
• W3213010911 hasAuthorship W3213010911A5087850908 @default.
• W3213010911 hasBestOaLocation W32130109111 @default.
• W3213010911 hasConcept C126322002 @default.
• W3213010911 hasConcept C141071460 @default.
• W3213010911 hasConcept C143998085 @default.
• W3213010911 hasConcept C2776329913 @default.
• W3213010911 hasConcept C2776839432 @default.
• W3213010911 hasConcept C2779134260 @default.
• W3213010911 hasConcept C2780401358 @default.
• W3213010911 hasConcept C2780850621 @default.
• W3213010911 hasConcept C3008058167 @default.
• W3213010911 hasConcept C524204448 @default.
• W3213010911 hasConcept C535046627 @default.
• W3213010911 hasConcept C71924100 @default.
• W3213010911 hasConcept C98274493 @default.
• W3213010911 hasConceptScore W3213010911C126322002 @default.
• W3213010911 hasConceptScore W3213010911C141071460 @default.
• W3213010911 hasConceptScore W3213010911C143998085 @default.
• W3213010911 hasConceptScore W3213010911C2776329913 @default.
• W3213010911 hasConceptScore W3213010911C2776839432 @default.
• W3213010911 hasConceptScore W3213010911C2779134260 @default.
• W3213010911 hasConceptScore W3213010911C2780401358 @default.
• W3213010911 hasConceptScore W3213010911C2780850621 @default.
• W3213010911 hasConceptScore W3213010911C3008058167 @default.
• W3213010911 hasConceptScore W3213010911C524204448 @default.
• W3213010911 hasConceptScore W3213010911C535046627 @default.
• W3213010911 hasConceptScore W3213010911C71924100 @default.
• W3213010911 hasConceptScore W3213010911C98274493 @default.
• W3213010911 hasIssue "Supplement 1" @default.
• W3213010911 hasLocation W32130109111 @default.
• W3213010911 hasOpenAccess W3213010911 @default.
• W3213010911 hasPrimaryLocation W32130109111 @default.
• W3213010911 hasRelatedWork W1581747141 @default.
• W3213010911 hasRelatedWork W2025625383 @default.
• W3213010911 hasRelatedWork W2025779517 @default.
• W3213010911 hasRelatedWork W2038387969 @default.
• W3213010911 hasRelatedWork W2070128988 @default.
• W3213010911 hasRelatedWork W2089759731 @default.
• W3213010911 hasRelatedWork W2326940307 @default.
• W3213010911 hasRelatedWork W2600169258 @default.
• W3213010911 hasRelatedWork W3181104117 @default.
• W3213010911 hasRelatedWork W4312228779 @default.
• W3213010911 hasVolume "138" @default.
• W3213010911 isParatext "false" @default.
• W3213010911 isRetracted "false" @default.
• W3213010911 magId "3213010911" @default.
• W3213010911 workType "article" @default.